Abstract
Pioglitazone is a thiazolidinedione (TZD) class of antidiabetic drug acting mainly through activation of PPARγ which is a member of family of ligand activated nuclear hormone receptors. Clofibrate is an antilipemic drug acting through activation of PPARα. Despite the impressive antidiabetic activity of TZD, several side effects are implicated to use of this drug on some patient. Dual acting PPARα/γ agonists have received increased attention to improve the profiles of the PPARγ agonists. Hence, we describe here synthesis of TZD and/or fibrate derivatives-containing homo-or copolymers, poly(TZD) 7, poly(TZD-MAA) 8, poly(TZD-FA) 9, poly(FA) 10, and poly(FA-MAA) 11. The contents of TZD unit in copolymers, poly(TZD-MAA) 8 and poly (TZD-FA) 9 were 25 and 19 mol %, respectively. The number average molecular weights of the polymers determined by GPC were in range from 466 to 12600 and the polydispersity indices were in the range of 1.2∼13.3.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., and Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebocontrolled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care, 23, 1605–1611 (2000).
Barnett, D., Craig, J. G., Robinson, D. S., and Rogers, M. P., Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br. J. Clin. Pharmacol., 4, 455–458 (1977).
Berger, J. and Moller, D. E., The mechanisms of action of PPARs. Annu. Rev. Med., 53, 409–435 (2002).
Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Smith, S. A., and Thurlby, P. L., [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977–3985 (1994).
Cox, S. L., Tesaglitazar: a promising approach in type 2 diabetes. Drugs Today (Barc), 42, 139–146 (2006).
Desvergne, B. and Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 20, 649–688 (1999).
Devasthale, P. V., Chen, S., Jeon, Y., Qu, F., Shao, C., Wang, W., Zhang, H., Cap, M., Farrelly, D., Golla, R., Grover, G., Harrity, T., Ma, Z., Moore, L., Ren, J., Seethala, R., Cheng, L., Sleph, P., Sun, W., Tieman, A., Wetterau, J. R., Doweyko, A., Chandrasena, G., Chang, S. Y., Humphreys, W. G., Sasseville, V. G., Biller, S. A., Ryono, D. E., Selan, F., Hariharan, N., and Cheng, P. T., Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. J. Med. Chem., 48, 2248–2250 (2005).
Ibrahimi, A., Teboul, L., Gaillard, D., Amri, E. Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimaldi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol., 46, 1070–1076 (1994).
Kersten, J. R., Toller, W. G., Gross, E. R., Pagel, P. S., and Warltier, D. C., Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am. J. Physiol. Heart Circ. Physiol., 278, H1218–H1224 (2000).
Kletzien, R. F., Clarke, S. D., and Ulrich, R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol., 41, 393–398 (1992).
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953–12956 (1995).
Ljung, B., Bamberg, K., Dahllof, B., Kjellstedt, A., Oakes, N. D., Ostling, J., Svensson, L., and Camejo, G., AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res., 43, 1855–1863 (2002).
Sohda, T., Momose, Y., Meguro, K., Kawamatsu, Y., Sugiyama, Y., and Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung, 40, 37–42 (1990).
Yajima, K., Hirose, H., Fujita, H., Seto, Y., Fujita, H., Ukeda, K., Miyashita, K., Kawai, T., Yamamoto, Y., Ogawa, T., Yamada, T., and Saruta, T., Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am. J. Physiol. Endocrinol. Metab., 284, E966–E971 (2003).
Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., and Horikoshi, H., Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem., 32, 421–428 (1989).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, Y., Kang, B. & Jeon, R. Synthesis of polymeric thiazolidinedione and fibrate conjugates. Arch. Pharm. Res. 31, 148–153 (2008). https://doi.org/10.1007/s12272-001-1133-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-001-1133-2